Cargando…
Interleukin-21: A New Mediator of Inflammation in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is an autoimmune disorder characterized by excessive production of a variety of autoantibodies and a wide range of clinical manifestations. Pathogenesis of SLE is complex and not fully understood. There is however evidence that B and T cells are critical to the dev...
Autores principales: | Sarra, Massimiliano, Monteleone, Giovanni |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905909/ https://www.ncbi.nlm.nih.gov/pubmed/20652041 http://dx.doi.org/10.1155/2010/294582 |
Ejemplares similares
-
Low-dose interleukin-2 therapy in systemic lupus erythematosus
por: La Cava, Antonio
Publicado: (2023) -
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer
por: Stolfi, Carmine, et al.
Publicado: (2011) -
T Cells, Interleukin-2 and Systemic Lupus Erythematosus—From Pathophysiology to Therapy
por: Mak, Anselm
Publicado: (2022) -
The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus
por: Kahlenberg, J Michelle, et al.
Publicado: (2011) -
Interleukin-23 and Th17 Cells in the Control of Gut Inflammation
por: Monteleone, Ivan, et al.
Publicado: (2009)